Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
67.27 K
Value Traded
-
Short % Float
0.98%
Days to Cover
1.0
-15.55%Week
+15.64%1 Month
+15.64%3 Month
+15.64%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
103.17 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
7.88 M
Float Shares
6.36 M
Insiders
23.62%
Institutions
22.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RTSN Catalyst Timeline
Dated clinical, regulatory and corporate events for Retension Pharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How RTSN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RTSN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Keller Eric L.Director, Officer (CHIEF EXECUTIVE OFFICER) | Buy | 20,800 423,377 held | $12.00 | 10/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RTSN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RTSN for Q2 2026. | ||||
RTSN Institutional Ownership Trends
RTSN Short Interest
Shares sold short, counted twice a month.
0.98%
Short % of Float
of tradable shares sold short
62.0K
Shares Sold Short
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
118.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RTSN ranks across every disease it competes in
Competitive Position is a premium feature
See how RTSN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRTSN News
-RTSN
Oct 9, 2026Retension Pharmaceuticals Announces Pricing of Initial Public Offering
Retension Pharmaceuticals has announced the pricing of its initial public offering, offering 3,750,000 shares at $12.00 each, aiming to raise $45 million. The funds will support the Phase 2b trial of RTN-001 for uncontrolled hypertension and prepare for a Phase 3 trial. The offering is set to close on October 13, 2026.
Read more →-RTSN
Sep 14, 2026Retension Pharmaceuticals Announces Formation of Scientific Advisory Board
Retension Pharmaceuticals has established a Scientific Advisory Board to support the clinical development of RTN-001, a treatment for hypertension. The board comprises leading experts in hypertension and cardiovascular diseases, who will provide strategic guidance during the ongoing Phase 2b trial. The formation of this board is expected to enhance the execution and impact of the trial.
Read more →-RTSN
Sep 10, 2026Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
Retension Pharmaceuticals announced the appointments of LeAnne Bloedon as EVP of Clinical Development and Operations and Kevin Schutz as VP of Regulatory Affairs. Both leaders bring extensive experience in cardiovascular therapies and regulatory strategy. Their expertise will support the ongoing Phase 2b trial of RTN-001, aimed at treating uncontrolled hypertension.
Read more →-RTSN
May 27, 2026Retension Pharmaceuticals Appoints Alison Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
Retension Pharmaceuticals appointed Alison D. Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer. Both leaders bring extensive experience to advance RTN-001, currently in a Phase 2b trial for hypertension. Schecter has a strong background in cardiovascular drug development, while Schwartz has significant financial expertise in biotech.
Read more →-RTSN
Aug 6, 2025Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001
Retension Pharmaceuticals announced the completion of a $15 million Series B financing to support its Phase 2b trial for RTN-001, targeting uncontrolled and resistant hypertension. The company also received a new U.S. patent for RTN-001, which is designed to enhance nitric oxide signaling. The upcoming trial aims to evaluate a once-daily formulation's efficacy and safety across multiple U.S. sites.
Read more →-RTSN
Aug 21, 2024Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension
Retension Pharmaceuticals closed a $10.4 million Series A funding round to advance RTN-001, a second-generation PDE5 inhibitor, into a Phase 2 clinical study for patients with uncontrolled hypertension. The drug has shown promising results in previous trials, demonstrating significant blood pressure reduction and good tolerability. The funding will support further efficacy studies and ongoing development efforts.
Read more →About Retension Pharmaceuticals, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next RTSN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime